0001213900-23-023822.txt : 20230329 0001213900-23-023822.hdr.sgml : 20230329 20230328214455 ACCESSION NUMBER: 0001213900-23-023822 CONFORMED SUBMISSION TYPE: POS AM PUBLIC DOCUMENT COUNT: 14 FILED AS OF DATE: 20230329 DATE AS OF CHANGE: 20230328 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SomaLogic, Inc. CENTRAL INDEX KEY: 0001837412 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 854298912 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: POS AM SEC ACT: 1933 Act SEC FILE NUMBER: 333-259954 FILM NUMBER: 23771555 BUSINESS ADDRESS: STREET 1: C/O CORVEX MANAGEMENT LP STREET 2: 667 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10065 BUSINESS PHONE: (212) 474 6724 MAIL ADDRESS: STREET 1: C/O CORVEX MANAGEMENT LP STREET 2: 667 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10065 FORMER COMPANY: FORMER CONFORMED NAME: CM Life Sciences II Inc. DATE OF NAME CHANGE: 20201221 POS AM 1 ea175884-posam_somalogic.htm POST-EFFECTIVE AMENDMENT NO. 4 TO FORM S-1

As filed with the Securities and Exchange Commission on March 28, 2023

Registration No. 333-259954

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

POST-EFFECTIVE AMENDMENT NO. 4

TO
FORM S-1
REGISTRATION STATEMENT
Under
The Securities Act of 1933

 

 

 

SOMALOGIC, INC.
(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   8732   85-4298912
(State or other jurisdiction of
incorporation or organization)
  (Primary Standard Industrial
Classification Code Number)
  (I.R.S. Employer
Identification Number)

 

2945 Wilderness Place,
Boulder, Colorado 80301
(303) 625-9000 

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

 

 

 

Troy Cox
Executive Chair
2945 Wilderness Place,
Boulder, Colorado 80301
(303) 625-9000

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

 

Copies to:

 

Charles D. Maguire, Jr.
Tyler F. Mark
Bryan Cave Leighton Paisner LLP
1700 Lincoln Avenue
Denver, CO 80203
(303) 861-7000
  Ruben Gutierrez
General Counsel
2945 Wilderness Place,
Boulder, Colorado 80301
(303) 625-9000

 

 

 

Approximate date of commencement of proposed sale to the public: From time to time after this registration statement becomes effective.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. 

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. 

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. 

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer     Accelerated filer  
  Non-accelerated filer     Smaller reporting company  
          Emerging growth company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. 

 

 

 

 

 

 

ADDITION OF EXHIBIT

 

This Post-Effective Amendment No. 4 to the Registration Statement on Form S-1 (Registration No. 333-259954) was filed to include as an exhibit to such S-1 the consent of Ernst & Young LLP to the use of its report dated March 28, 2023 with respect to the consolidated financial statements of SomaLogic, Inc. and its subsidiaries (the “Company”) included in the Annual Report on Form 10-K of the Company for the year ended December 31, 2022 in such registration statement and the related prospectus. The report of Ernst & Young LLP was filed in the Prospectus Supplement dated March 28, 2023 filed pursuant to Rule 424(b)(3). The consent of Ernst & Young LLP is filed as Exhibit 23.1 herewith.

 

1

 

 

PART II

 

INFORMATION NOT REQUIRED IN PROSPECTUS 

 

Item 16. Exhibits and Financial Statement Schedules

 

Exhibits. We have filed the exhibits listed on the accompanying Exhibit Index of this registration statement.

 

Exhibit       Incorporated by Reference
Number   Description   Form   Exhibit   Filing Date
2.1†   Merger Agreement, as amended by the First Amendment thereto dated May 12, 2021 and the Second Amendment thereto dated July 15, 2021 (included as Annex A to the Proxy Statement/Prospectus which forms a part of the S-4/A).   S-4/A   2.1   08/05/2021
2.2††   Agreement and Plan of Merger, dated as of July 25, 2022, by and among SomaLogic, Merger Sub I, Merger Sub II, Palamedrix, and the Securityholder Representative   8-K   2.1   07/27/2022
3.1   Second Amended and Restated Certificate of Incorporation of SomaLogic, Inc.   8-A/A   3.1   09/01/2021
3.2   Amended and Restated Bylaws of SomaLogic, Inc.   8-A/A   3.2   09/01/2021
4.1   Specimen Common Stock Certificate.   S-4/A   4.1   08/05/2021
4.2   Warrant Agreement.   8-K   10.1   02/26/2021
4.3   Description of Company’s Securities   10-K   4.3   3/29/2022
5.1   Legal Opinion of Bryan Cave Leighton Paisner LLP   POS AM   5.1   07/22/2022
10.1+   SomaLogic, Inc. 2021 Omnibus Incentive Plan (included as Annex C to the Proxy Statement/Prospectus forming a part of the S-4/A).   S-4/A   10.1   08/05/2021
10.2+   SomaLogic, Inc. Employee Stock Purchase Plan (included as Annex D to the Proxy Statement/Prospectus forming a part of the S-4/A).   S-4/A   10.2   08/05/2021
10.3+   Form of Stock Appreciation Rights Agreement pursuant to the SomaLogic, Inc. 2021 Omnibus Incentive Plan.   S-4/A   10.3   08/05/2021
10.4+   Form of Incentive Stock Option Award Agreement under the SomaLogic, Inc. 2021 Omnibus Incentive Plan.   S-4/A   10.4   08/05/2021
10.5+   Form of Restricted Stock Unit Award Agreement under the SomaLogic, Inc. 2021 Omnibus Incentive Plan.   S-4/A   10.5   08/05/2021
10.6+   Form of Restricted Stock Award Agreement under the SomaLogic, Inc. 2021 Omnibus Incentive Plan.   S-4/A   10.6   08/05/2021
10.7+   Form of Non-Qualified Stock Option Award Agreement under the SomaLogic, Inc. 2021 Omnibus Incentive Plan.   S-4/A   10.7   08/05/2021
10.8+   SomaLogic, Inc. 2009 Equity Incentive Plan.   S-4/A   10.8   08/05/2021
10.9+   Form of Non-Statutory Stock Option Agreement under the SomaLogic, Inc. 2009 Equity Incentive Plan.   S-4/A   10.9   08/05/2021
10.10+   Form of Incentive Stock Option Agreement under the SomaLogic, Inc. 2009 Equity Incentive Plan.   S-4/A   10.10   08/05/2021
10.11+   SomaLogic, Inc. 2017 Equity Incentive Plan.   S-4/A   10.11   08/05/2021
10.12+   Form of Option Agreement (Incentive Stock Option or Non-statutory Stock Option) under the SomaLogic, Inc. 2017 Equity Incentive Plan.   S-4/A   10.12   08/05/2021
10.13+   Severance Agreement, dated September 1, 2020, between SomaLogic, Inc. and Lawrence Gold.   S-4/A   10.13   08/05/2021
10.14+   First Amendment to Severance Agreement, dated December 4, 2020, between SomaLogic, Inc. and Lawrence Gold.   S-4/A   10.14   08/05/2021
10.15+   Employment Agreement, dated April 20, 2020, between SomaLogic, Inc. and Roy Smythe.   S-4/A   10.15   08/05/2021
10.16+   Employment Agreement, dated April 20, 2020, between SomaLogic, Inc. and Stephen Williams.   S-4/A   10.16   08/05/2021
10.17+   Employment Agreement, dated April 20, 2020, between SomaLogic, Inc. and Melody Harris.   S-4/A   10.17   08/05/2021
10.18+   Amendment to Employment Agreement dated June 28, 2021 between SomaLogic, Inc. and Roy Smythe.   S-4/A   10.18   08/05/2021
10.19+   Amendment to Employment Agreement dated June 28, 2021 between SomaLogic, Inc. and Stephen Williams.   S-4/A   10.19   08/05/2021
10.20+   Amendment to Employment Agreement dated June 28, 2021 between SomaLogic, Inc. and Melody Harris.   S-4/A   10.20   08/05/2021

 

II-1

 

 

10.21   Form of Subscription Agreement.   8-K   10.1   03/29/2021
10.22   Form of Stockholder Lock-Up Agreement.   8-K   10.2   03/29/2021
10.23   Form of Stockholder Support Agreement.   8-K   10.3   03/29/2021
10.24   Sponsor Support Agreement dated March 28, 2021.   8-K   10.4   03/29/2021
10.25   Forfeiture Agreement dated March 28, 2021.   8-K   10.5   03/29/2021
10.26   Form of Amended and Restated Registration Rights Agreement.   8-K   10.6   03/29/2021
10.27   Investment Management Trust Agreement dated February 22, 2021.   8-K   10.2   02/26/2021
10.28   Registration Rights Agreement dated February 22, 2021.   8-K   10.3   02/26/2021
10.29   Private Placement Warrants Purchase Agreement dated February 22, 2021.   8-K   10.4   02/26/2021
10.30   Letter Agreement dated February 22, 2021.   8-K   10.5   02/26/2021
10.31   Forward Purchase Agreement dated February 22, 2021.   8-K   10.6   02/26/2021
10.32   Forward Purchase Agreement dated February 22, 2021.   8-K   10.7   02/26/2021
10.33††   Master Collaboration Agreement, dated September 20, 2019, between SomaLogic, Inc. and Novartis Pharma AG.   S-4/A   10.33   08/05/2021
10.34††   Amended and Restated Master SomaScan Discovery Services Agreement, dated October 13, 2020, between SomaLogic, Inc. and Amgen Inc.   S-4/A   10.34   08/05/2021
10.35††   Supply Agreement, dated April 8, 2019, between SomaLogic, Inc. and Agilent Technologies, Inc., as amended by that certain First Amendment to Supply Agreement, dated October 1, 2021, between SomaLogic, Inc. and Agilent Technologies, Inc.   10-K   10.34   03/29/2022
10.36††   Supply Agreement, dated August 15, 2017, between SomaLogic, Inc. and Global Life Sciences Solutions USA LLC, as amended by that certain First Amendment to Catalog Product Support Agreement, dated September 14, 2020, between SomaLogic, Inc. and Global Life Sciences Solutions USA LLC   10-K   10.35   03/29/2022
10.37††#   Collaboration Agreement, dated December 31, 2021, among SomaLogic, Inc., Illumina Cambridge, Ltd. and Illumina, Inc.   10-K   10.36   03/29/2022
10.38††#   First Amendment to Collaboration Agreement, dated November 14, 2022, among SomaLogic, Inc., Illumina Cambridge, Ltd. and Illumina, Inc.    10-K   10.38   3/28/2023
10.39†   Lease Agreement, dated February 10, 2022, between SomaLogic Operating Co., Inc. and Louisville 1 Industrial Owner, LLC.   8-K   10.1   2/16/2022
10.40†   Lease Agreement, dated February 10, 2022, between SomaLogic Operative Co., Inc. and Louisville 2 Industrial Owner, LLC.   8-K   10.2   2/16/2022
10.41+   Employment Agreement, dated October 17, 2022, between SomaLogic, Inc. and Troy Cox.   8-K   10.1   10/17/2022
10.42+   Key Employee Severance Plan, dated October 17, 2022.   8-K   10.2   10/17/2022
21.1   Subsidiaries of the Company.   10-K   21.1   03/29/2022
23.1   Consent of Ernst & Young LLP, independent registered accounting firm for SomaLogic, Inc.            
23.2   Consent of Bryan Cave Leighton Paisner LLP (included as part of Exhibit 5.1).   POS AM   23.2   07/22/2022
24.1   Power of Attorney (included with the signature page of the Form S-1 filed on October 1, 2021).*   S-1       10/01/2021
101.INS   Inline XBRL Instance Document.            
101.SCH   Inline XBRL Taxonomy Extension Schema Document.            
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.            
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.            
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.            
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.            
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).            

 

*Previously filed.

Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5).
  The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.

†† The Company has omitted portions of the exhibit as permitted under Regulation S-K Item 601(b)(10). The Registrant agrees to furnish on a supplemental basis an unredacted copy of this exhibit and its materiality and privacy or confidentiality analysis if requested by the SEC.
+ Management contract or compensatory plan or arrangement.

# Portions of this exhibit have been omitted pursuant to a request for confidential treatment. Omitted material for which confidential treatment has been requested has been filed separately with the SEC.

 

II-2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Post-Effective Amendment No. 4 to registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boulder, State of Colorado, on March 28, 2023.

 

  SOMALOGIC, INC.
   
  By: /s/ Troy Cox
    Executive Chair

 

Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment No. 4 to the registration statement on Form S-1 has been signed by the following persons in the capacities and on the dates indicated:

 

Signature   Title   Date
         
*   Executive Chair   March 28, 2023
Troy Cox   (Principal Executive Officer)    
         
/s/ Shaun Blakeman   Chief Financial Officer   March 28, 2023
Shaun Blakeman   (Principal Financial and Accounting Officer)    
         
*   Director   March 28, 2023
Robert Barchi        
         
*   Director   March 28, 2023
Eli Casdin        
         
*   Director   March 28, 2023
Charles M. Lillis        
         
*   Director   March 28, 2023
Anne Margulies        
         
*   Director   March 28, 2023
Ted Meisel        
         
*   Director   March 28, 2023
Richard Post        
         
*   Director   March 28, 2023
Roy Smythe        

 

* By: /s/ Shaun Blakeman  
  Shaun Blakeman  
  Attorney-in-Fact  
     
  /s/ Ruben Gutierrez  
  Ruben Gutierrez  
  Attorney-in-Fact  

 

 

II-3

 

true POS AM 0001837412 0001837412 2022-01-01 2022-06-30
EX-23.1 2 ea175884ex23-1_somalogic.htm CONSENT OF ERNST & YOUNG LLP, INDEPENDENT REGISTERED ACCOUNTING FIRM FOR SOMALOGIC, INC

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the reference to our firm under the caption “Experts” and to the use of our report dated March 28, 2023, in Amendment No. 4 to the Registration Statement (Form S-1 No. 333-259954) and related Prospectus of SomaLogic, Inc. for the registration of 48,413,333 shares of its common stock; 5,013,333 warrants to purchase shares of its common stock; 10,533,333 shares of its common stock underlying warrants; and 838,100 shares of its common stock underlying options.

 

/s/ Ernst & Young LLP

 

Denver, Colorado

March 28, 2023

EX-101.SCH 3 slgc-20220630.xsd XBRL SCHEMA FILE 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.DEF 4 slgc-20220630_def.xml XBRL DEFINITION FILE EX-101.LAB 5 slgc-20220630_lab.xml XBRL LABEL FILE EX-101.PRE 6 slgc-20220630_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information
6 Months Ended
Jun. 30, 2022
Document Information Line Items  
Entity Registrant Name SOMALOGIC, INC.
Document Type POS AM
Amendment Flag true
Amendment Description This Post-Effective Amendment No. 4 to the Registration Statement on Form S-1 (Registration No. 333-259954) was filed to include as an exhibit to such S-1 the consent of Ernst & Young LLP to the use of its report dated March 28, 2023 with respect to the consolidated financial statements of SomaLogic, Inc. and its subsidiaries (the “Company”) included in the Annual Report on Form 10-K of the Company for the year ended December 31, 2022 in such registration statement and the related prospectus. The report of Ernst & Young LLP was filed in the Prospectus Supplement dated March 28, 2023 filed pursuant to Rule 424(b)(3). The consent of Ernst & Young LLP is filed as Exhibit 23.1 herewith.
Entity Central Index Key 0001837412
Entity Filer Category Non-accelerated Filer
Entity Small Business true
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Incorporation, State or Country Code DE
XML 8 ea175884-posam_somalogic_htm.xml IDEA: XBRL DOCUMENT 0001837412 2022-01-01 2022-06-30 SOMALOGIC, INC. DE Non-accelerated Filer true true false This Post-Effective Amendment No. 4 to the Registration Statement on Form S-1 (Registration No. 333-259954) was filed to include as an exhibit to such S-1 the consent of Ernst & Young LLP to the use of its report dated March 28, 2023 with respect to the consolidated financial statements of SomaLogic, Inc. and its subsidiaries (the “Company”) included in the Annual Report on Form 10-K of the Company for the year ended December 31, 2022 in such registration statement and the related prospectus. The report of Ernst & Young LLP was filed in the Prospectus Supplement dated March 28, 2023 filed pursuant to Rule 424(b)(3). The consent of Ernst & Young LLP is filed as Exhibit 23.1 herewith. true POS AM 0001837412 EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 10 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://somalogic.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports ea175884-posam_somalogic.htm ea175884ex23-1_somalogic.htm slgc-20220630.xsd slgc-20220630_def.xml slgc-20220630_lab.xml slgc-20220630_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea175884-posam_somalogic.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 10 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "slgc-20220630_def.xml" ] }, "inline": { "local": [ "ea175884-posam_somalogic.htm" ] }, "labelLink": { "local": [ "slgc-20220630_lab.xml" ] }, "presentationLink": { "local": [ "slgc-20220630_pre.xml" ] }, "schema": { "local": [ "slgc-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd" ] } }, "elementCount": 13, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 10, "memberCustom": 0, "memberStandard": 0, "nsprefix": "slgc", "nsuri": "http://somalogic.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "ea175884-posam_somalogic.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://somalogic.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "ea175884-posam_somalogic.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description", "terseLabel": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://somalogic.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://somalogic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://somalogic.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://somalogic.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://somalogic.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://somalogic.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://somalogic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://somalogic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://somalogic.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://somalogic.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://somalogic.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://somalogic.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "slgc_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://somalogic.com/20220630", "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001213900-23-023822-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-023822-xbrl.zip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end